Cigarette Smoking Alters Expression of MicroRNAs
gene expression under physiological conditions. 9, 10 Supporting this theory, essential roles for microRNAs have been discovered in most cellular processes, including cell proliferation, development, differentiation, and apoptosis. [11] [12] [13] [14] Moreover, aberrant microRNA expression has emerged as a hallmark of human diseases, starting with cancers but now including cardiovascular disease and inflammatory lung disease. [15] [16] [17] [18] Most reported microRNA expression patterns in humans come from microRNA detection in cells or tissue from the target organs of disease, including the global downregulation of microRNA expression in alveolar macrophages and bronchial alveolar epithelium from smokers. 19, 20 In recent years, microRNAs were discovered to have reproducible signals and to be stable in blood. 21, 22 These results have motivated efforts to profile circulating microRNAs in disease states, with the goal of harnessing their potential as noninvasive diagnostic biomarkers. Thus far, small cohort studies have profiled microRNA expression in induced sputum and plasma from cigarette smokers. 12, 23 We sought to elucidate a comprehensive, whole blood-based microRNA profile for cigarette smoking that may (1) have predictive value for smoking-associated diseases and (2) shed light on the microRNA-mediated alterations in gene expression theorized to link smoking with smoking-related disease phenotypes. We hypothesized that microRNA profiling of whole blood would capture disrupted gene regulatory networks relevant to the inflammatory and immune responses that link the direct effects of cigarette smoking to target organ damage and smoking-related systemic diseases. To this end, we characterized a whole blood-derived microRNA signature of cigarette smoking in 5023 Framingham Heart Study participants and evaluated the top microRNAs in relation to smoking-associated clinical phenotypes, smoking-associated gene expression, and inflammatory signaling in lung tissue.
Methods

Study Samples
The Framingham Heart Study, a community-based prospective study of cardiovascular disease and associated risk factors, was initiated in 1948 and has enrolled 3 generations of participants. [24] [25] [26] On-site evaluations of the Offspring and Third Generation cohort participants, including anthropometric data and biological sample collections, have been conducted every 4 to 8 years. Samples from Offspring cohort examination 8 (2005-2008 ; n=2571) and Third Generation cohort examination 2 (2008-2011; n=3245 ) with complete smoking status data (n=5816) were eligible for analysis. Nonfasting blood specimens were collected and stored at −80°C until assayed. Total RNA was isolated from peripheral whole blood samples (mean yield=3.50±1.66 µg) in PAXgene tubes (PreAnalytiX, Hombrechtikon, Switzerland) by Asuragen, Inc. (Austin, TX). RNA quality was assessed by total yield (>2 µg), 260/280 ratio (1.7-2.2; absorbance reading in spectrophotometer at 260 and 280 nm; this ratio gives information about the purity of an RNA sample with 1.6-2.0 ratio showing ideal RNA purity), RNA integrity (7) (8) (9) (10) , amplification quality (>5 μg), and cDNA size (median=400 nucleotides). After excluding 8 samples with poor RNA quality, a total of 5808 samples were available for further analysis ( Figure IA in the Data Supplement).
Clinical Measures
Participant smoking status was stratified as current, former, or never. Current smokers were defined as those who reported smoking on average at least 1 cigarette per day in the year before the Framingham Heart Study clinic examination, former smokers were individuals who reported smoking on average at least 1 cigarette per day in the past but had not smoked in the past year, and never smokers reported never smoking. Serum CRP (C-reactive protein) was measured in the Offspring cohort at examination 8 and Third Generation at examination 2 using a high sensitivity Dade-Behring BN 100 nephelometer. 27 Serum interleukin-6 was quantified in Offspring cohort participants at examination 8 using the Quantikine HS Interleukin-6 Immunoassay kit (R&D Systems, Bio-Techne, Minneapolis, MN). 28 Interleukin-6 was not measured in the Third Generation cohort at examination 2. Intra-assay coefficients of variation for inflammatory marker measurements were <9.2%. 29 Forced expiratory volume at 1 second (FEV 1 ) and forced vital capacity (FVC) were measured on the Offspring cohort at examination 8 using a water-filled spirometer (Collins Medical, Inc., Braintree, MA) and personal computer software (S&M Instruments, Doylestown, PA) and on the Third Generation at examination 2 using a dry rolling-seal spirometer and Collins 2000 Pus/SQL software (Collins Medical, Inc.). In both examinations, the highest value among acceptable efforts was used as per the American Thoracic Society-European Respiratory Society guidelines. 30 In addition, the same staff training and quality control activities were used for both of these examinations. Raw values for FEV 1 and FVC were examined as a percentages of the predicted values, with predicted values calculated using standard reference equations derived from healthy never smokers in the NHANES III study (National Health and Nutrition Examination Survey). 31 The FEV 1 / FVC ratio was calculated from the highest acceptable individual measures. A dichotomous airflow obstruction variable was defined as the combination of FEV 1 <lower limit of normal and the FEV 1 /FVC ratio <lower limit of normal, with lower limits of normal defined on the basis of published NHANES III data.
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Expression Profiling
MicroRNA profiling was performed using targeted TaqMan microR-NA assays (Applied Biosystems, Foster City, CA). A high-throughput reverse transcription quatitative polymerase chain reaction platform was used, which uses integrated fluidic circuits to perform miniaturized reactions at high efficiency with a batch size of 96 samples versus 96 microRNA targets (BioMark, Fluidigm Corp, San Francisco, CA). Profiling was completed at Boston University, Boston, MA, and the University of Massachusetts, Worcester, MA (laboratory of Dr Jane Freedman). Reverse transcription and preamplification reactions were conducted in 2 separate pools (A and B), containing primers for 176 and 157 microRNAs, respectively, and performed according to standard TaqMan protocols. MicroRNAs were assayed in subpanels (A1-2 and B1-2), each of which contained 4 housekeeping RNAs. Excellent reproducibility was demonstrated in preliminary profiling of 24 samples with 96 microRNA assays (mean coefficient of variation ≈3.5%). The analytic pipeline included an additional pilot study in which 754 microRNAs were measured on 455 Offspring cohort samples (batch 1). The detectable subset of 345 microRNAs was measured in the remaining Offspring cohort samples (n=2116) and the Third Generation cohort samples (n=3245; batch 2). Of these, 5729 samples passed quality control measures for microRNA profiling. Removed samples included those with <100 detectable microRNAs in batch 1 or <20 detectable microRNAs in batch 2, as well as 9 samples recommended for removal by the laboratory technician during microRNA profiling. Samples with missing cell counts (n=705) and missing smoking status (n=1) were excluded, leaving a final sample size of 5023 ( Figure IA in the Data Supplement). From the set of detected microRNAs, we filtered out microRNAs (n=56) expressed in ˂500 participants. Outlier microRNA expression levels (threshold cycle [C T ] ≥5 SDs from the mean C T ) were treated as missing (a total of 32 outliers for 6 microRNAs were treated as missing). We further excluded 6 microRNAs that were identified as small nucleolarRNAs or tRNA fragments in the latest version of miRBase. 7 The final microRNA panel consisted of 283 microRNAs ( Figure IB in the Data Supplement). To normalize microRNA expression data, raw C T values were adjusted for 4 technical variables: RNA isolation batch, RNA quality, RNA concentration, and 260/280 ratio. This method was chosen for the following reasons. First, reliable reference or housekeeping RNAs have not been well characterized in whole blood. Second, exploratory models run on pilot study data using (1) adjustment for the small nuclear RNA RNU48 and (2) global mean normalization with mean C T values for ≈50 experimental microRNAs both resulted in overfitting. Third, variance analysis demonstrated that these technical variables accounted for the greatest degree of variation in C T values (40%-60%).
mRNA expression profiling of whole blood-derived RNA using the Affymetrix Human Exon Array ST 1.0 was performed as described previously. 32, 33 Briefly, amplified cDNA was generated using the WT-Ovation Pico RNA Amplification System and processed with the WT-Ovation Exon Module (NuGEN, San Carlos, CA) in an automated genechip array station. Affymetrix Human Exon 1.0 ST microarrays were hybridized, washed, and scanned (Affymetrix, Santa Clara, CA). Microarray data for 17 873 genes were collected using the robust multichip average method, and 5626 samples passed mRNA quality controls ( Figure IA in the Data Supplement). Data were normalized with robust multichip average and further adjusted for technical covariates, as described previously. 32, 33 Cell Culture, MicroRNA Transfection, and Cytokine Analysis
To evaluate the impact of smoking-associated microRNAs on the expression of inflammatory mediators in the lung, human lung epithelial A549 (ATCC CCL-185) cells were maintained in Ham's F12 media (Life Technologies, Thermo Fischer Scientific Corp., Carlsbad, CA) supplemented with 10% fetal bovine serum (Life Technologies) and 1x penicillin/streptomycin at 37°C and 5% CO 2 . Cells grown in 6-well tissue culture dishes were transfected with human microRNA mimetics (Dharmacon, Inc., Lafayette, CO) of nontargeting sequence (CN-001000-01-05) or 1 of 3 smoking-associated microRNAsmiR-744-3p (MIMAT0004946), miR-1180-3p (MIMAT0005825), or miR-1285-3p (MIMAT0005876)-using DharmaFECT1 to achieve a final concentration of 50 nmol/L. Smoking-associated microRNAs were selected for this functional experiment based on the strength of observed associations with smoking status, inflammatory biomarkers, and lung function and the putative involvement of these microRNAs in inflammatory and immune pathways based on gene ontology (GO) results from coexpression and target prediction analyses. After 24 hours of transfection, cells were stimulated with 10 ng/mL recombinant human tumor necrosis factor-α (R&D Systems, Bio-Techne, Minneapolis, MN) or vehicle for 6 hours. A panel of cytokines was measured in the collected cell supernatants using a multiplex bead array (R&D Systems). Cytokine expression was analyzed using a Liquichip100 (Qiagen, Hilden, Germany).
Statistical Methods
Statistical analyses were performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC) or R software version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). 34 Linear mixed effects models with a random effect term to account for covariance because of familial relationships (the lmekin function in R) were used to test the association of microRNA expression with cigarette smoking as a 3-level categorical variable (current/former/never). Expression of each microRNA was the dependent variable, and smoking status was the exposure. Covariates included age, sex, cohort, 4 technical covariates (RNA isolation batch [50 levels], RNA quality, RNA concentration, and 260/280 ratio), and complete blood cell count variables. Complete blood cell counts were imputed from mRNA expression values via partial least square prediction, with cross-validated prediction accuracy estimates ranging from 0.25 to 0.89.
False discovery rate (FDR) and q values were estimated using the Benjamini-Hochberg method. 35 An FDR threshold of 0.10 was applied to identify significant microRNAs in the primary analysis. We then performed pairwise comparisons in (1) current versus never smokers, (2) current versus former smokers, and (3) former versus never smokers. MicroRNAs that passed the screening threshold were considered significant in pairwise comparisons at FDR <0.10. To demonstrate the reproducibility of observed associations, we conducted internal validation by splitting our sample into 2 groups of equal size by family into discovery and validation sets, with ≈2500 individuals in each, and analyzing microRNA associations in each set independently.
We used linear mixed effects models with a random effect term to account for covariance because of familial relationships (the lmekin function in R) to assess the association of smoking-related microRNAs with inflammatory markers and pulmonary function measures. MicroRNA expression level was treated as the exposure variable. For inflammatory biomarker analyses, the log e -transformed serum concentration of CRP or interleukin-6 was treated as the outcome. For pulmonary function analyses, the outcome variables were FEV 1 , FVC, the ratio of FEV 1 /FVC, and airflow obstruction, with raw values of FEV 1 and FVC examined as a percentages of the predicted values as described above. 31 All models were adjusted for age, sex, cohort, smoking status, imputed complete blood cell counts, and the 4 technical covariates described above. For associations with clinical phenotypes, the number of tests was modest, so the Bonferroni method was used to correct for multiple testing. The P value threshold (P<1.4×10 −3 ) was calculated by dividing 0.05 by the number of significant smoking-associated microRNAs (6)× the 6 clinical phenotypes tested (0.05/[6*6]).
For microRNA-mRNA coexpression analysis, pairwise coexpression of all profiled microRNAs and mRNAs was conducted using linear mixed effects models with fix effect terms, including age, sex, and technical covariates, and with a random effect term to account for covariance because of genetic relationships in extended pedigrees (the lmekin function in R). MicroRNA expression was the dependent variable, mRNA expression was the independent variable, and models were adjusted for age, sex, cohort, technical covariates, and imputed complete blood cell counts. Split sample analysis was conducted, with significant coexpressed pairs in both discovery and validation sets (≈2800 samples each) identified from the large number of coexpressed pairs at the conservative threshold of FDR <0.01. The coexpression results were then overlapped with the set of significant microRNAs (FDR <0.10) and significant mRNAs (FDR <0.05) to identify an mRNA-microRNA coexpression signature for cigarette smoking. The more stringent FDR threshold for significant mRNAs than for significant microRNAs reflects the far greater number of mRNAs associated with smoking. To further interrogate the identified mRNA-microRNA correlations, we crossreferenced these pairs with 3 microRNA target databases: miRDB and miRNAorg (predicted targets) and miRTarBase (experimentally validated targets).
Separate GO enrichment analyses were conducted on the sets of smoking-associated mRNAs coexpressed with each of our smokingassociated microRNAs based on functional classifications using all biological process terms in the GO Consortium database. 36 The enrichment P value threshold for significance (P<6.1×10 −5 ) was determined by the Bonferroni method, adjusting for 825 biological process terms in the GO database. GO analysis was also performed on coexpressed genes in which the mRNA was a predicted or validated target of its coexpressed microRNA. Because of the much smaller sample size, the analysis was performed on the aggregate results (rather than separately for each individual microRNA) and used a more liberal threshold (FDR <0.05) to define significant pathways. Network figures were generated using the JAVA-based visual analytic software tool ProteoLens. 37 For determining the potential effects of microRNA mimetic transfection on cytokine expression in lung epithelial cells, data were pooled from independent microRNA transfection experiments (n=3), which were analyzed and presented together. Analyses used log e -transformed data in a 2-way ANOVA with random block design across both factors (transfection and stimulation) to account for experiment-to-experiment variability. Dunnett test was applied post hoc to compare cytokine concentrations from cells transfected with microRNA mimetics to similarly stimulated cells that were instead transfected with nontargeting control. Statistical analyses were performed using Prism 6.0 (GraphPad Software, Inc., San Diego, CA). A conservative P value threshold was set at P<0.01. Cigarette Smoking Alters Expression of MicroRNAs
Study Approval
All participants gave informed consent for participation in this study and collection of biosamples for genetic/genomic analysis. The study protocol was approved by the Boston University Medical Center Institutional Review Board.
Results
Study Sample Characteristics
Of 5023 participants (54.0% women; mean age, 55±13 years) with data for microRNA profiling, 10% were current cigarette smokers (n=524), 41% were former smokers (n=2079), and 48% were never smokers (n=2420; Table 1 ). Former smokers (mean age=60 years) were older than current smokers (51 years) or never smokers (52 years). Imputed white blood cell count was higher in current smokers (mean white blood cell=7.2) versus former smokers (mean white blood cell=6.1) and never smokers (mean white blood cell=5.9). Levels of inflammatory markers were higher and pulmonary function measures were lower in current versus former versus never smokers. Airflow obstruction was highest in current smokers (14.9%), lower in former smokers (6.2%), and lowest in never smokers (2.8%).
MicroRNA Associations With Smoking Status
Six microRNAs were associated with 3-level smoking status (Table 2) . Each was detectable in >4400 participant samples with the exception of miR-342-5p, which was measurable in 1115 samples. Five of these microRNAs were associated with current versus never smokers, with all but 1 (miR-342-5p) underexpressed in current smokers. MiR-423-5p was the only marker differentially expressed in former versus never smokers, with decreased expression in former smokers. The distribution of microRNA C T values by smoking status is shown in Figure II in the Data Supplement. Split sample analyses demonstrated a consistent pattern for t statistics of microRNAs considered separately in the discovery and validation sets. For each significant microRNA, the directionality and scale of effect sizes in discovery and validation sets were consistent with the combined results ( Table I in the Data Supplement).
MicroRNA Associations With Smoking-Related Clinical Phenotypes
Four smoking-associated microRNAs showed negative associations with log e -transformed serum concentration of CRP: ), miR-423-5p (P=2.0×10 −8 ), and miR-25-5p (P=1.3×10 −7 ; Table 3 ). One microRNA in our smoking signature, miR-1285-3p, was positively associated with the proinflammatory biomarker interleukin-6 (P=7.9×10 −6 ). Analysis of significant microRNAs in relation to pulmonary function measures revealed that miR-1180 was negatively associated with prevalence of airflow obstruction (P=1.8×10 −3 ) and positively associated with FEV 1 (P=9.5×10 −3 ) at a marginally significant level (Table 4) .
MicroRNA Correlations With Smoking-Related Genes
Expression levels of ≈8200 genes (≈50% of those measured) were associated with cigarette smoking at FDR <0.05. The majority of highly differentially expressed genes were upregulated in the context of cigarette smoking. Coexpression analysis identified 4137 smoking-associated gene transcripts that were coexpressed with at least 1 of the 345 microRNAs measured and 2116 smoking-associated gene transcripts that were coexpressed with ≥1 of the 6 smoking-associated microRNAs (at FDR <0.01 in the discovery and validation sets). There were 1666 genes coexpressed with miR-25-5p, 524 with miR-1285-3p, 491 with miR-1180, 446 with miR-181a-2-3p, 275 with miR-423-5p, and none with miR-342-5p. We further identified 116 coexpressed pairs in which the mRNA was a predicted (n=111) or validated (n=5) target of the correlated microRNA. There were 17 predicted targets for miR-1180, 13 predicted for miR-181a-2-3p, 32 predicted for miR-1285-3p, 5 predicted for miR-25-5p, and 5 validated and 44 predicted for miR-423-5p (Table II in 
GO Analysis
Independent GO enrichment analyses were conducted on the sets of smoking-associated mRNA transcripts that were coexpressed with each of our top microRNAs. Figure 1 shows the network of GO categories for the coexpressed mRNAs. Tables III and IV in the Data Supplement provide detailed information on the GO analysis and the overlapping genes in each category. The expression of miR-1180, our top smoking-associated microRNA, was negatively correlated with the expression of genes involved in monocyte differentiation (enrichment P=3.1×10 −5 ). MiR-181a-2-3p expression was positively correlated with expression of genes that function in immune cell-mediated cytotoxicity (enrichment P=5.7×10 −5 ). MiR-181a-2-3p was negatively correlated with genes involved in viral response (enrichment P=4.7×10 −6 ). Coexpressed mRNAs for the remaining microRNAs were enriched for a variety of common pathways, for example, regulation of transcription and protein processing, which are known to be preferentially targeted by randomly selected sets of microRNAs. 1.17
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C indicates current; C T , threshold cycle; F, former; FDR, false discovery rate; and N, never. *We used the Benjamini-Hochberg method to calculate q values (SAS Proc MULTTEST), and we applied a threshold of FDR <0.10 for the 3-level analysis. microRNAs are sorted by ascending q value. †Estimated β coefficients represent the mean differences in microRNA C T values between specific smoking groups, where higher C T values reflect lower microRNA expression.
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We also performed GO enrichment analysis on the set of microRNA-mRNA coexpressed pairs in which the mRNA was a predicted (n=112) or validated (n=5) target of the correlated microRNA. In the aggregate results, the GO term with the greatest fold enrichment was T-cell homeostasis (enrichment P=4.2×10 −4 ; q value=0.038) ( Table V  in 
MicroRNA Effects on Inflammatory Mediators
To determine whether individual microRNAs that are associated with cigarette smoking status and smoking-induced inflammation could be sufficient to modulate the expression vof inflammatory mediators, we measured cytokine elaboration by human lung epithelial cells separately transfected with mimetics for miR-1180 and miR-1285-3p A nontargeting microRNA mimetic served as a negative control. Expression levels of 8 cytokines were quantified in cell supernatants: interleukin-6, interleukin-8, granulocyte macrophage ) was determined by the Bonferroni method (0.05/6 smoking-associated microRNAs×6 clinical phenotypes tested]).
‡Marginally significant P values. Cigarette Smoking Alters Expression of MicroRNAs colony-stimulating factor, granulocyte colony-stimulating factor, chemokine C-C motif ligand 2, chemokine C-C motif ligand 20, chemokine C-X-C motif ligand (CXCL) 5, and CXCL6. Transfection of miR-1180 reduced production of granulocyte macrophage colony-stimulating factor (P=0.01) in stimulated cells (Figure 2 ). Basal levels of CXCL5 and CXCL6 were increased in response to transfection of both microRNAs, and miR-1285-3p transfection also increased production of CXCL5 (P=0.003) in stimulated cells. Other cytokines tested, including interleukin-6, interleukin-8, granulocyte colony-stimulating factor, chemokine C-C motif ligand 20, and chemokine C-C motif ligand 2, were not significantly affected by the microRNAs examined.
Discussion
Cigarette smoking acutely promotes oxidative stress, as evidenced by increased plasma peroxides and decreased antioxidants, and chronic smoking leads to systemic inflammation characterized by the upregulation of circulating inflammatory cells (primarily neutrophils, lymphocytes, and platelets), inflammatory mediators, and acute-phase proteins. 39, 40 To test our hypothesis that microRNAs may have predictive value for smoking-associated diseases, we characterized a comprehensive microRNA signature of cigarette smoking using high-throughput reverse transcription quatitative polymerase chain reaction profiling of whole blood RNA from a large, population-based sample.
We identified 6 microRNAs that were characteristically dysregulated in the context of smoking, 5 of which were downregulated in smokers versus nonsmokers (Table 2) . These results are supported by the widespread downregulation of microRNAs found in cigarette smoke-exposed lung tissue from mouse models and human samples.
12,20,41-43 Our whole blood-derived microRNA signature of cigarette smoking is novel, and the results show little overlap with previous studies. This lack of concordance is common across microRNA-smoking studies and can be explained by diverse tissue sources, nonuniform tobacco exposures, and different microRNA platforms. Two of our top hits-miR-1180 and miR-1285-3p-are recently identified microRNAs 44, 45 that have been linked to cancer-specific gene regulatory networks; miR-1180 has been shown to inhibit cell apoptosis in human hepatocellular carcinoma both in vivo and in vitro while miR-1285-3p inhibits the expression of tumor suppressor p53. 46, 47 MiR-181a-2-3p is involved in the immune response as a positive regulator of B-cell development and T-cell sensitivity. 48, 49 The remaining 3 microRNAs have been associated with multiple human cancers, and miR-423-5p and miR-25-5p have been linked to heart disease. 50, 51 Dysregulation of circulating miR-342-5p has been found in autoimmune conditions; miR-342-5p has been shown to promote inflammatory activation of macrophages in atherosclerotic lesions, consistent with our finding that current cigarette smokers exhibited higher miR-342-5p expression compared with never smokers. [52] [53] [54] Whole blood is readily accessible and can be stored for later RNA extraction. This stable form of blood-derived RNA can be isolated with relative ease and high purity, making microRNA results in whole blood particularly amenable to clinical translation. MicroRNAs detected in whole blood may be present in leukocytes, platelets, erythrocytes, and cellfree plasma. 55 In previous work using the same microRNA detection platform and a small sample of healthy volunteers, several of our coauthors defined the distributions of >600 circulating microRNAs in whole blood, peripheral blood mononuclear cells, platelets, plasma, and serum. 56 Of our significant microRNAs, 3 (miR-181a-2-3p, miR-25-5p, and miR-423-5p) Figure 1 . Network of gene ontology (GO) categories for smoking-associated mRNAs coexpressed with smoking-associated microRNA. Smoking-associated gene transcripts that are coexpressed with ≥1 smoking-associated microRNAs and represented by ≥1 GO categories. Only gene transcripts belonging to GO categories meeting the Bonferroni-corrected enrichment P value threshold of P<10 −5 are included (see Tables III and IV in the Data Supplement for GO results). Blue lines denote negative correlations while purple lines indicate positive correlations between microRNA and mRNA expression. This figure was drawn by ProteoLens. 37 were detectable in whole blood and peripheral blood mononuclear cells only while the remaining 3 (miR-1180, miR-1285-3p, and miR-342-5p) were additionally detectable in platelets. 56 These data suggest that our microRNA expression patterns are largely derived from leukocytes and secondarily from platelets. We may also have captured signals from small amounts of cell-free microRNAs, which can be released from or targeted to smoking-relevant tissues. Because microRNA profiling in whole blood cannot distinguish cell type-specific effects, further studies are needed to localize the observed microRNA patterns to specific blood components.
To explore the functional significance of the cigarette smoking-related microRNAs, we evaluated their associations with smoking-related clinical phenotypes: 2 biomarkers of systemic inflammation and 4 measures of pulmonary function. Population-based studies have demonstrated that the systemic inflammatory state induced by cigarette smoking is associated with increased levels of acute-phase proteins (CRP, fibrinogen, etc) and proinflammatory cytokines (interleukin-6, tumor necrosis factor-α, etc) in the peripheral circulation. [57] [58] [59] In the Framingham Heart Study, serum CRP and interleukin-6 levels were significantly higher in current cigarette smokers than never smokers. 60 We investigated the relationships of smoking-associated microRNAs to systemic inflammation by relating our significant microRNAs to serum concentrations of CRP and interleukin-6. Four microRNAs were negatively associated with CRP: miR-1180, miR-181a-2-3p, miR-423-5p, and miR-25-5p (Table 3 ). In support of these findings, mir-181a-2-3p has been shown to downregulate inflammatory factors in monocytes and macrophages. 61 MiR-25-5p is downregulated in human airway smooth muscle cells in response to proinflammatory stimuli and is proposed to regulate expression of multiple inflammatory mediators in these cells. 62 Elevated levels of miR-423-5p were found in surgical lung biopsies of idiopathic pulmonary fibrosis, in which inflammation may play a critical role. 63, 64 One microRNA, miR-1285-3p, was positively associated with interleukin-6 ( Table 3) . Additional studies may shed light on the discrepancy between microRNA associations with CRP and with interleukin-6 observed in our cross-sectional analysis.
Cigarette smoking is an established cause of impaired pulmonary function. 65 Smoking is the major risk factor for chronic obstructive pulmonary disease, which is defined by irreversible airflow obstruction and is the fourth leading cause of death worldwide. 66 Smoking-induced chronic obstructive pulmonary disease is driven by inflammation because the activation of neutrophils, macrophages, and lymphocytes and associated secretion of inflammatory mediators trigger a chronic inflammatory response in the lung. 67 Premature senescence of epithelial and immune cells, the latter of which heightens inflammation, has also been implicated in the pathogenesis of smoking-induced chronic obstructive pulmonary disease. 68 Nevertheless, the causal mechanisms and molecular players underlying chronic obstructive pulmonary disease progression in the lungs of smokers have yet to be elucidated. Analysis of our significant microRNAs in relation to pulmonary function Multiplex cytokine bead array analysis of A549 cell culture supernatants after transfection with nontargeting (NT), miR-1180, or miR-1285-3p mimetics. Cells were stimulated 24 h post-transfection with vehicle or 10 ng/mL recombinant human TNF-α for 6 h. Squares, triangles, and circles represent data collected from 3 independent experiments, normalized to the cytokine concentrations in the negative control group (NT vehicle). The * indicates P<0.01 (significant P values shown) when compared with NT control within a given stimulation group as determined by a 2-way ANOVA followed by Dunnett test, using raw rather than normalized values. CCL indicates chemokine C-C motif ligand; CXCL, chemokine C-X-C motif ligand; GM-CSF, granulocyte macrophage colony-stimulating factor; IL, interleukin; and TNF, tumor necrosis factor. Cigarette Smoking Alters Expression of MicroRNAs measures revealed that miR-1180 was negatively associated with airflow obstruction and positively associated with FEV 1 at a marginally significant level (Table 4 ). Although our crosssectional results suggest that microRNAs may serve as biomarkers for smoking-related inflammation and target organ damage, we cannot deduce with certainty the directionality of observed associations.
To better understand the mechanistic connections between dysregulated microRNA expression, systemic inflammation, and lung dysfunction in the context of cigarette smoking, we identified >1600 smoking-associated genes that were coexpressed with ≥1 of our top microRNAs in whole blood. GO analysis of the mRNAs correlated with each microRNA showed enrichment for immune-related pathways among genes coexpressed with miR-1180 and miR-181a-2-3p ( Figure 1 ; Table III in the Data Supplement). MiR-1180 expression was negatively correlated with expression of genes involved in differentiation of several immune cell types. MiR-181a-2-3p level was positively correlated with genes for immune cell-mediated cytotoxicity and negatively correlated with viral response genes ( Figure 1 ; Table III in the Data Supplement). We further interrogated the regulatory networks that these microRNAs may be involved in by cross-referencing our coexpressed pairs with microRNA target databases. We identified 116 coexpressed pairs in which the mRNA was a predicted or validated target of its correlated microRNA. GO analysis of the predicted targets highlighted T-cell homeostasis, and 2 of 4 overlapping genes in this pathway were predicted targets of miR-1180 (Tables II and V in  the Data Supplement) .
We hypothesize that our microRNA-mRNA coexpressed pairs, especially those involving predicted targets, describe gene regulatory networks primarily localized to leukocytes and platelets. Loss-of-function experiments have demonstrated the broad importance of microRNAs in development, including the developmental programs of B cells, T cells, and other leukocytes. 69 Moreover, specific immuno-microRNAs, including miR-181a-2-3p, have been shown to regulate lymphocyte differentiation and function. 70 Although platelets are anuclear, they contain cytoplasmic mRNA, perform protein translation, and express >280 microRNAs, and platelet microRNA-mRNA coexpression profiles have been correlated with platelet reactivity. 71, 72 Taken together, these bioinformatic results suggest that smoking-induced dysregulation of the aforementioned microRNAs may play a mediating role in inflammatory responses by modulating microRNA-specific gene regulatory networks in leukocytes and, to a lesser extent, platelets.
Our study has several strengths, including the large community-based cohort of young, middle-aged, and older adults and the ascertainment of microRNAs, inflammatory markers, and pulmonary function measures adhering to rigorous quality control protocols. Our cross-sectional results highlight smoking-associated microRNAs that have the potential to serve as noninvasive biomarkers of smoking exposure or smoking-related diseases. Moreover, our functional evidence suggesting that these microRNAs can mediate lung inflammation combined with our bioinformatic identification of coexpressed predicted gene targets is a first step toward determining disease-relevant microRNA targets that may be funneled into emerging clinical pipelines for RNA interference-based therapeutics. 73 Our results highlight select smoking-associated microRNAs and are consistent with the hypothesis that smoking-associated microRNAs function as mediators of cigarette smoking-induced inflammation and downstream target organ damage (Figure 3) . Additional functional studies are needed to assess whether these microRNAs are causally associated with smoking-related phenotypes.
We also acknowledge several limitations. Our study participants were largely of European ancestry, and the generalizability of our findings to other races/ethnicities is uncertain. Because we analyzed results across a large number of microRNAs, mRNAs, and microRNA-mRNA coexpressed pairs, our study is susceptible to both false-positive and false-negative findings despite adjustment for multiple testing. MicroRNA profiling was conducted on whole blood and as such may not reflect tissue-specific patterns of expression-even though we adjusted for differential blood cell composition imputed from mRNA expression values. Although we present evidence of robust validation of our cross-sectional results based on analysis of split samples for discovery and validation, our study lacks external replication. We cannot exclude residual confounding or establish causal associations in the cross-sectional results. Our functional study also has limitations: small sample size (n=3 independent experiments); single time-point collection; restriction to 1 cell type; and reliance on microRNA overexpression, which could target genes that would not be affected under physiological conditions.
The proposed identification of gene regulatory networks involving coexpressed microRNA-mRNA pairs assumes temporal sequence and spatial colocalization, neither of which can be proven by cross-sectional correlations in whole blood. It is possible that different cell types or blood components account for changes in microRNA and mRNA expression and that tissue specificity precludes their joint participation in intracellular regulatory networks. Observed correlations may also indicate common consequences of smoking-induced damage rather than mutual involvement in mediating pathways. We addressed these issues, in part, by identifying coexpressed pairs in which the mRNA was a predicted target of the correlated microRNA. However, we were underpowered to study microRNA-specific pathway enrichment, and the functional Because gene repression by microRNAs is generally modest and tunable, whether a target is actually affected depends on the local concentrations of both microRNA and mRNA, such that predicted relationships may be irrelevant in a given tissue. 74 Furthermore, predicted target analysis only addresses direct targeting relationships outside the context of intact cells, but microRNAs act within complex regulatory networks that cannot be fully captured by first-order correlations. 75 Because our bioinformatics analysis linked the smokingassociated microRNAs to inflammation and because microRNAs can target transcripts for cytokines and for signaling intermediates upstream of cytokine expression, [76] [77] [78] [79] [80] we tested whether these microRNAs were capable of modulating inflammatory cytokines relevant to cigarette smoking. To our knowledge, none of these microRNAs has previously been connected to pulmonary inflammation. We observed microRNA-specific effects on cytokine elaboration by lung cells for the 2 microRNAs tested, with miR-1180 reducing production of granulocyte macrophage colony-stimulating factor, and miR-1180 and miR-1285-3p increasing levels of CXCL5 and CXCL6 ( Figure 2 ). Although miR-1285-3p was positively associated with interleukin-6 in the cross-sectional analysis, overexpression of miR-1285-3p in lung cells did not significantly affect interleukin-6 levels. Granulocyte macrophage colonystimulating factor drives alveolar macrophage maturation and innate immune activities in the lung. 81 CXCL5 and CXCL6 are lung epithelium-derived ligands for the CXCR2 receptor on neutrophils; these chemokines recruit their cognate leukocytes to the lungs during pulmonary inflammation. 82, 83 Each of these cytokine pathways influences cigarette smokinginduced inflammation and disease, [84] [85] [86] [87] [88] so their regulation by microRNA changes could impact the health of cigarette smokers. The cytokine changes suggest that decreased levels of these microRNAs could skew smoking-induced inflammation toward mononuclear cell inflammation and away from neutrophilic infiltration. Future studies are needed to determine the mechanisms responsible for regulating microRNA levels affected by cigarette smoking, to identify the transcripts targeted by these microRNAs that modulate cytokine expression, and to elucidate the net effects of these multiple microRNA changes on integrated inflammatory responses to cigarette smoke. Our results provide evidence in support of the hypothesis that the microRNAs associated with smoking, inflammation, and pulmonary function in an observational study are functionally capable of dictating expression of the cytokines governing inflammation and disease in cigarette smokers.
